Amyloid protein targeting CAR (chimeric antigen receptor) capable of reducing inflammatory response and application thereof, nucleic acid, carrier, macrophage and microglial cell
By designing chimeric antigen receptor (CAR) and pluripotent stem cell differentiation technology to target amyloid β protein, the inflammatory response and transplant risk problems of targeted amyloid β protein therapy in the existing technology are solved, and efficient Aβ is achieved Phaleptophagocytosis and reducing neuroinflammation provide a new treatment for Alzheimer's disease.
Patent Information
- Application Number
- CN202411465070.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-21
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing amyloid β-protein antibodies or fusion proteins are prone to trigger immune inflammatory responses when treating Alzheimer's disease, and have poor clinical effects. Hematopoietic stem cell transplantation has a low targeting ability and a risk of graft-versus-host disease.
A chimeric antigen receptor (CAR) targeting amyloid β protein is designed, consisting of the ectocyte domain, CD8a hinge domain, CD8a transmembrane domain and intracellular domain, including scFv and TYRO3 and AXL of anti-amyloid β protein Or MERTK intracellular domain, used to improve the Aβ phagocytosis of microglia and reduce neuroinflammatory responses, and to obtain terminally differentiated microglia through pluripotent stem cell differentiation to avoid graft-versus-host disease.
It significantly improves the phagocytic ability of microglia to Aβ, reduces the neuroinflammatory response, provides a new solution for Alzheimer's disease treatment, and uses cells obtained through in vitro differentiation for transplantation, reducing the risk of graft-versus-host disease .
Smart Images

Figure CN118978606A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a CAR targeting amyloid protein and reducing inflammatory response, and its application, nucleic acid, vector, macrophage and microglia. Background Art
[0002] 1. Antibodies or fusion proteins targeting amyloid-β (Aβ) for the treatment of Alzheimer's disease (AD) In 2021, the US FDA approved the marketing of Aducanumab, the world's first drug targeting Aβ, which can reduce the deposition of Aβ plaques in the brains of AD patients and reduce the rate of decline in patients' cognitive and memory abilities. After Aducanumab, the US FDA approved the second drug targeting Aβ, Lecanemab, in 2023, and the third drug targeting Aβ, Donanemab, in July 2024. In addition, there are several monoclonal antibody drugs in the clinical research stage, such as Gantenerumab.
[0003] In 2022, Hyuncheol et al. reported the fusion protein αAβ–Gas6, which acts as a bridge between Aβ and the microglial TAM receptor family, enabling microglia to clear Aβ protein without causing an immune inflammatory response.
[0004] The disadvantages of the above technologies are: ① While antibodies activate microglia to phagocytose Aβ, they also induce microglia to release proinflammatory cytokines, resulting in side effects; ② Most antibodies have poor actual clinical therapeutic effects; ③ Antibodies or fusion proteins require multiple doses in actual applications, increasing the treatment costs for patients.
[0005] 2. Cell therapy for Alzheimer's disease In 2023, Priyanka et al. reported that by replacing microglia in the AD mouse model with hematopoietic stem cell transplantation, Aβ protein was reduced in the mouse brain and cognitive ability was improved.
[0006] The disadvantages of this technology are: ① The microglia differentiated from the transplanted hematopoietic stem cells have not been modified and have a low ability to target Aβ protein; ② Hematopoietic stem cells are precursor cells and will randomly differentiate into other types of cells in the body, which may cause risks such as graft-versus-host disease.
[0007] In view of this, the present invention is proposed. Summary of the invention
[0008] The first purpose of the present invention is to provide a chimeric antigen receptor (CAR) targeting amyloid β protein, which can significantly improve the ability of microglia to phagocytize and clear Aβ protein; induce microglia to produce anti-inflammatory immune response and reduce neuroinflammatory response; and provide a new solution for the treatment of Alzheimer's disease.
[0009] The second object of the present invention is to provide applications of the chimeric antigen receptor.
[0010] The third object of the present invention is to provide a nucleotide.
[0011] The fourth object of the present invention is to provide a carrier.
[0012] A fifth object of the present invention is to provide a macrophage.
[0013] The sixth object of the present invention is to provide a microglia cell.
[0014] In order to achieve the above objectives, the following technical solutions are adopted: In a first aspect, the present invention provides a chimeric antigen receptor targeting amyloid β protein, which comprises, from N-terminus to C-terminus, an extracellular domain, a hinge domain of CD8a, a transmembrane domain of CD8a, and an intracellular domain; The extracellular domain includes a CD8a signal peptide and an anti-amyloid β protein scFv from the N-terminus to the C-terminus; the amino acid sequence of the scFv is shown in SEQ ID NO.1; The intracellular domain includes the intracellular domain of TYRO3, the intracellular domain of AXL or the intracellular domain of MERTK; The chimeric antigen receptor is a human chimeric antigen receptor or a mouse chimeric antigen receptor; In the human chimeric antigen receptor, the amino acid sequence of the signal peptide of CD8a is shown in SEQ ID NO.2, the amino acid sequence of the hinge domain of CD8a is shown in SEQ ID NO.3, the amino acid sequence of the transmembrane domain of CD8a is shown in SEQ ID NO.4, the amino acid sequence of the intracellular domain of TYRO3 is shown in SEQ ID NO.5, the amino acid sequence of the intracellular domain of AXL is shown in SEQ ID NO.6, and the amino acid sequence of the intracellular domain of MERTK is shown in SEQ ID NO.7; In the chimeric antigen receptor of the mouse, the amino acid sequence of the signal peptide of CD8a is shown as SEQ ID NO.8, the amino acid sequence of the hinge domain of CD8a is shown as SEQ ID NO.9, the amino acid sequence of the transmembrane domain of CD8a is shown as SEQ ID NO.10, the amino acid sequence of the intracellular domain of TYRO3 is shown as SEQ ID NO.11, the amino acid sequence of the intracellular domain of AXL is shown as SEQ ID NO.12, and the amino acid sequence of the intracellular domain of MERTK is shown as SEQ ID NO.13.
[0015] As a further technical solution, the chimeric antigen receptor further comprises a fluorescent label; The fluorescent tag includes EGFP.
[0016] As a further technical solution, the fluorescent tag is linked to the intracellular domain via a connecting peptide; The amino acid sequence of the connecting peptide is shown in SEQ ID NO.14.
[0017] In a second aspect, the present invention provides the use of the chimeric antigen receptor in the following a or b: a. Preparation of products for removing amyloid β protein; b. Prepare products that reduce neuroinflammatory responses.
[0018] In a third aspect, the present invention provides a nucleotide comprising a nucleotide sequence encoding the chimeric antigen receptor.
[0019] In a fourth aspect, the present invention provides a vector carrying the nucleotide.
[0020] In a fifth aspect, the present invention provides a macrophage, which carries the nucleotide, or contains the vector, or expresses the chimeric antigen receptor.
[0021] The macrophages can target and engulf amyloid-β protein in an antigen-dependent manner and reduce neuroinflammatory responses.
[0022] In a sixth aspect, the present invention provides a microglial cell, wherein the microglial cell carries the nucleotide, or contains the vector, or expresses the chimeric antigen receptor.
[0023] The microglia can target and engulf amyloid-β protein in an antigen-dependent manner and reduce neuroinflammatory responses.
[0024] As a further technical solution, the microglia are obtained by differentiation of induced pluripotent stem cells, comprising the following steps: Inducing pluripotent stem cells to form embryoid bodies by culturing them in a first culture medium; then culturing the embryoid bodies in a second culture medium to induce differentiation of hematopoietic stem and progenitor cells; then culturing them in a third culture medium to induce the production of hematopoietic stem and progenitor cells and inducing their differentiation into myeloid lineage; finally, collecting the differentiated hematopoietic stem and progenitor cells, and culturing them in a fourth culture medium to induce differentiation into microglia; The first culture medium comprises: human BMP4 10 ng / mL, Y-27632 10 μM and STEMdiff™ APEL™2 culture medium; The second culture medium comprises: human BMP4 10 ng / mL, human FGF-2 10 ng / mL, human SCF 100 ng / mL, human VEGF-A 50 ng / mL and STEMdiff™ APEL™2 culture medium; The third culture medium comprises: human FGF-2 10 ng / mL, human SCF 50 ng / mL, human VEGF-A 50 ng / mL, human IL-3 25 ng / mL, human M-CSF 50 ng / mL, human GM-CSF 50 ng / mL, human IGF-1 10 ng / mL and STEMdiff™APEL™2 culture medium; The fourth culture medium comprises: ITS-G 2 wt %, glutamine 1x (gibco, 35050061), non-essential amino acids 1x (gibco, 11140050), mercaptoethanol 100 μM, B27 2 wt % (gibco, 17504044), N2 2 wt % (gibco, 17502001), human M-CSF 50 ng / mL, human IL-34 50 ng / mL, human TGF-beta 1 50 ng / mL and DMEM / F12 culture medium; The second culture medium is cultured for 4-6 days; The third culture medium is cultured for 22-26 days.
[0025] As a further technical solution, the second culture medium is replaced every 3 days; The third culture medium was replaced every 2 days.
[0026] Compared with the prior art, the present invention has the following beneficial effects: The chimeric antigen receptor targeting amyloid β protein provided by the present invention can improve the phagocytic ability of macrophages to Aβ when expressed in macrophages. Expression in microglia can enable microglia to have the ability to target Aβ, significantly improve the phagocytic ability of Aβ, and reduce neuroinflammatory response; a large number of microglia can be obtained by in vitro differentiation of pluripotent stem cells, and the microglia obtained by in vitro differentiation are terminally differentiated cells with clear components, and will not cause risks such as graft-versus-host disease when used for cell transplantation. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0028] Figure 1 Schematic diagram of the structure of CAR targeting Aβ; Figure 2 CAR-RAW264.7 can effectively phagocytose Aβ in vitro; Figure 3 CAR-HMC3 can effectively phagocytose Aβ in vitro; Figure 4 Differentiate human pluripotent stem cells into microglia in vitro; Figure 5 CAR-microglia can reduce neuroinflammatory responses; Figure 6 CAR-iMGL can phagocytize amyloid-β protein in mice. DETAILED DESCRIPTION
[0029] The embodiments of the present invention will be described in detail below in conjunction with the embodiments and examples, but it will be appreciated by those skilled in the art that the following embodiments and examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified, proceed according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0030] Chimeric Antigen Receptor (CAR): It is mainly composed of three parts: the extracellular antigen binding region, the transmembrane region, and the intracellular signal transduction region. The extracellular region is a single chain variable region domain (single chain Fvdomain, scFv), which has the function of specifically recognizing and binding to tumor-specific antigens. The transmembrane region is usually composed of the immunoglobulin superfamily, such as CD8 or CD28. The intracellular signal transduction region is mainly composed of co-stimulatory factors, such as 4-1BB or CD28 commonly used in CAR-T cells, and signal activation regions such as CD3ζ. After the immune cells loaded with chimeric antigen receptors bind to the surface antigens of tumor cells, the extracellular antigen binding region transmits the signal to the intracellular signal activation region, initiating the immune cell activation response.
[0031] In a first aspect, the present invention provides a chimeric antigen receptor targeting amyloid β protein, which comprises, from N-terminus to C-terminus, an extracellular domain, a hinge domain of CD8a, a transmembrane domain of CD8a, and an intracellular domain; The extracellular domain includes a CD8a signal peptide and an anti-amyloid β protein scFv from the N-terminus to the C-terminus; the amino acid sequence of the scFv is shown in SEQ ID NO.1: DIQMTQSPSSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKGGGGSGGGGSGGGGSEVQ LVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS (SEQ ID NO.1).
[0032] The intracellular domain includes the intracellular domain of TYRO3, the intracellular domain of AXL or the intracellular domain of MERTK; The chimeric antigen receptor is a human chimeric antigen receptor or a mouse chimeric antigen receptor; The sequences of the various regions in the human chimeric antigen receptor are as follows: The amino acid sequence of the signal peptide of CD8a is shown in SEQ ID NO.2: MALPVTALLLPLALLLHAARP (SEQ ID NO. 2).
[0033] The amino acid sequence of the hinge domain of CD8a is shown in SEQ ID NO.3: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO. 3).
[0034] The amino acid sequence of the transmembrane domain of CD8a is shown in SEQ ID NO.4: IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO. 4).
[0035] The amino acid sequence of the intracellular domain of TYRO3 is shown in SEQ ID NO.5: LRKRRKETRFGQAFDSVMARGEPAVHFRAARSFNRERPERIEATLDSLGISDELKEKLEDVLIPEQQFTLGRMLGKGEFGSVREAQLKQEDGSFVKVAVKMLKADIIASSD IEEFLREAACMKEFDHPHVAKLVGVSLRSRAKGRLPIPMVILPFMKHGDLHAFLLASRIGENPFNLPLQTLIRFMVDIACGMEYLSSRNFIHRDLAARNCMLAEDMTVCVA DFGLSRKIYSGDYYRQGCASKLPVKWLALESLADNLYTVQSDVWAFGVTMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQPPECMEDVYDLMYQCWSADPKQRPSFTCLR MELENILGQLSVLSASQDPLYINIERAEEPTAGGSLELPPGRDQPYSGAGDGSGMGAVGGTPSDCRYILTPGGLAEQPGQAEHQPESPLNETQRLLLLQQGLLPHSSC (SEQ IDNO.5).
[0036] The amino acid sequence of the intracellular domain of AXL is shown in SEQ ID NO.6: HRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA (SEQ ID NO.6).
[0037] The amino acid sequence of the intracellular domain of MERTK is shown in SEQ ID NO.7.
[0038] KRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEELQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFS HPNVIRLLVCIEMSSQGIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPV KWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPLDRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEG LAQGSTLAPLDLNIDPDSIIIASCTPRAAISVVTAEVHDSKPHEGRYILNGGSEEWEDLTSAPSAAVTAEKNSVLPGERLVRNGVSWSHSSMLPLGSSLPDELLFADDSSEGSEVLM (SEQ ID NO.7).
[0039] The sequences of the various regions in the mouse chimeric antigen receptor are as follows: The amino acid sequence of the signal peptide of CD8a is shown in SEQ ID NO.8: MASPLTRFLSLNLLLLGESIILGSGEA (SEQ ID NO. 8).
[0040] The amino acid sequence of the hinge domain of CD8a is shown in SEQ ID NO.9: SSVVPVLQKVNSTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIYI (SEQ ID NO. 9).
[0041] The amino acid sequence of the transmembrane domain of CD8a is shown in SEQ ID NO.10: WAPLAGICVALLLSLIITLI (SEQ ID NO. 10).
[0042] The amino acid sequence of the intracellular domain of TYRO3 is shown in SEQ ID NO.11: LRKRRKETRFGQAFDSVMARGEPAVHFRAARSFNRERPERIEATLDSLGISDELKEKLEDVLIPEQQFTLGRMLGKGEFGSVREAQLKQEDGSFVKVAVKMLKADIIASSDIEEFLREAACMKEFDHPHVAKLVGVSLRSRAKGRLPIPMVILPFMKHGDLHAFLLASRIGENPFNLPLQTLVRFMVDIACGMEYLSSRNFIHRDLAARNCMLAEDMTVCVADFGLSRKIYSGDYYRQGCASKLPVKWLALESLADNLYTVHSDVWAFGVTMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQPPECMEEVYDLMYQCWSADPKQRPSFTCLRMELENILGHLSVLSTSQDPLYINIERAEQPTESGSPEVHCGERSSSEAGDGSGVGAVGGIPSDSRYIFSPGGLSESPGQLEQQPESPLNENQRLLLLQQGLLPHSSC (SEQ ID NO.11).
[0043] The amino acid sequence of the intracellular domain of AXL is shown in SEQ ID NO.12 as follows: HRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSDREGFPEPVVILPFMKHGDLHSFLLYSRLGDQPVFLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPVDCLDGLYALMSRCWELNPRDRPSFAELREDLENTLKALPPAQEPDEILYVNMDEGGSHLEPRGAAGGADPPTQPDPKDSCSCLTAADVHSAGRYVLCPSTAPGPTLSADRGCPAPPGQEDGA (SEQ ID NO.12).
[0044] The amino acid sequence of the intracellular domain of MERTK is shown in SEQ ID NO.13.
[0045] ALRRRVQETKFGGAFSEEDSQLVVNYRAKKSFCRRAIELTLQSLGVSEELQNKLEDVVIDRNLLVLGKVLGEGEFGSVMEGNLKQEDGTSQKVAVKTMKLDNFSQREIEEFLSEAACMKD FNHPNVIRLLGVCIELSSQGIPKPMVILPFMKYGDLHTFLLYSRLNTGPKYIHLQTLLKFMMDIAQGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMP VKWIAIESLADRVYTSKSDVWAFGVTMWEITTRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYDIMYSCWSADPLDRPTFSVLRLQLEKLSESLPDAQDKESIIYINTQLLESCEG IANGPSLTGLDMNIDPDSIIASCTPGAAVSVVTAEVHENNLREERYILNGGNEEWEDVSSTPFAAVTPEKDGVLPEDRLTKNGVSWSHHSTLPLGSPSPDELLFVDDSLEDSEVLM (SEQ ID NO.13).
[0046] In some optional embodiments, the chimeric antigen receptor further comprises a fluorescent tag; The fluorescent tag includes but is not limited to EGFP.
[0047] Fluorescent labeling facilitates identification of chimeric antigen receptor expression.
[0048] In some optional embodiments, the fluorescent tag is linked to the intracellular domain via a connecting peptide; The amino acid sequence of the connecting peptide is shown in SEQ ID NO.14: EGRGSLLTCGDVEENPGP (SEQ ID NO. 14).
[0049] In a second aspect, the present invention provides the use of the chimeric antigen receptor in the following a or b: a. Preparation of products for removing amyloid β protein; b. Prepare products that reduce neuroinflammatory responses.
[0050] The chimeric antigen receptor targeting amyloid β protein provided by the present invention can improve the phagocytic ability of macrophages to Aβ when expressed in macrophages. When expressed in microglia, microglia can have the ability to target Aβ, significantly improve the phagocytic ability of Aβ, and reduce neuroinflammatory response.
[0051] In a third aspect, the present invention provides a nucleotide comprising a nucleotide sequence encoding the chimeric antigen receptor.
[0052] The nucleotide sequence is capable of expressing the chimeric antigen receptor of the present invention.
[0053] In a fourth aspect, the present invention provides a vector carrying the nucleotide.
[0054] The vector can be used for targeted delivery of target genes to achieve expression of the chimeric antigen receptor of the present invention in host cells.
[0055] In some optional embodiments, the vector comprises a lentiviral vector.
[0056] In a fifth aspect, the present invention provides a macrophage, which carries the nucleotide, or contains the vector, or expresses the chimeric antigen receptor.
[0057] The macrophages can target and engulf amyloid-β protein in an antigen-dependent manner and reduce neuroinflammatory responses.
[0058] In a sixth aspect, the present invention provides a microglial cell, wherein the microglial cell carries the nucleotide, or contains the vector, or expresses the chimeric antigen receptor.
[0059] The microglia can target and engulf amyloid-β protein in an antigen-dependent manner and reduce neuroinflammatory responses.
[0060] In some optional embodiments, the microglia are obtained by differentiation of induced pluripotent stem cells, comprising the following steps: Inducing pluripotent stem cells to form embryoid bodies by culturing them in a first culture medium; then culturing the embryoid bodies in a second culture medium to induce differentiation of hematopoietic stem and progenitor cells; then culturing them in a third culture medium to induce the production of hematopoietic stem and progenitor cells and inducing their differentiation into myeloid lineage; finally, collecting the differentiated hematopoietic stem and progenitor cells, and culturing them in a fourth culture medium to induce differentiation into microglia; The first culture medium comprises: human BMP4 10 ng / mL, Y-27632 10 μM and STEMdiff™ APEL™2 culture medium; The second culture medium comprises: human BMP4 10 ng / mL, human FGF-2 10 ng / mL, human SCF 100 ng / mL, human VEGF-A 50 ng / mL and STEMdiff™ APEL™2 culture medium; The third culture medium comprises: human FGF-2 10 ng / mL, human SCF 50 ng / mL, human VEGF-A 50 ng / mL, human IL-3 25 ng / mL, human M-CSF 50 ng / mL, human GM-CSF 50 ng / mL, human IGF-1 10 ng / mL and STEMdiff™APEL™2 culture medium; The fourth culture medium comprises: ITS-G 2 wt %, glutamine 1x (gibco, 35050061), non-essential amino acids 1x (gibco, 11140050), mercaptoethanol 100 μM, B27 2 wt % (gibco, 17504044), N2 2 wt % (gibco, 17502001), human M-CSF 50 ng / mL, human IL-34 50 ng / mL, human TGF-beta 1 50 ng / mL and DMEM / F12 culture medium; The second culture medium is cultured for 4-6 days; The third culture medium is cultured for 22-26 days.
[0061] In some optional embodiments, the second culture medium is replaced every 3 days; The third culture medium was replaced every 2 days.
[0062] This method is capable of producing microglia in large quantities.
[0063] In a specific embodiment, the microglia are obtained by differentiation of induced pluripotent stem cells, comprising the following steps: Day 0 The six-well plate was pre-coated with Matrigel (Corning #354277). Human iPSC cells were cultured in the Matrigel-coated six-well plate with mTeSR (STEMCELL Technologies) medium until the confluence was 60%-80%, digested with TryplE Select (ThermoFisher SCIENTIFIC) at room temperature for 5 minutes, neutralized with mTeSR medium, and pipetted into a single cell suspension. The cells were counted and the required number of cells was calculated according to 8000 cells per well. After centrifugation, the Pre-Differentiation medium (first culture medium) was resuspended at 60 μL per well. The cells were transferred to a 96-well U-bottom culture plate (Corning), and then the culture plate was centrifuged at 500 xg for 3 minutes. The cells were observed to aggregate at the bottom of the culture plate, and then placed in an incubator (5% CO2, 37°C) to induce embryoid body (EB) formation.
[0064] Day 1 Gently aspirate 2 / 3 of the medium in the culture plate and add 100 μL of Hematopoietic Differentiation Medium-1 (second medium). Replace the medium every 3 days.
[0065] Day 6 Gently aspirate 2 / 3 of the culture medium in the culture plate and add 100 μL of Hematopoietic Differentiation Medium-2 (the third culture medium). At this time, vacuoles can be seen in EBs, indicating that the differentiation effect is good.
[0066] Day 9 If the differentiation goes smoothly, the EB volume and vacuolar volume will increase significantly. Transfer the EB to a six-well plate pre-coated with matrix gel (Corning #354277), add 16 EBs to each well, and culture with fresh Hematopoietic Differentiation Medium-2 medium. The next day after the transfer, the EB will adhere to the wall, and then a large number of suspended cells will appear. Continue to culture for 21 days, replace the fresh Hematopoietic Differentiation Medium-2 medium every 2 days, and collect the suspended cells in the supernatant into a new 6-well plate. The collected suspended cells are cultured with Microglia Differentiation Medium (fourth culture medium) medium, and the culture medium is replaced every 3 days until microglia are obtained.
[0067] The present invention is further described below by means of specific examples and comparative examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0068] Example 1 1. Design of CAR structure targeting Aβ The CAR structure includes an extracellular domain, a transmembrane domain, and an intracellular domain.
[0069] For the extracellular domain of CAR, we selected Aducanumab, an antibody approved by the US FDA for marketing, and designed a scFv (Single-ChainFragment Variable, amino acid sequence as shown in SEQ ID NO.1) targeting Aβ based on its variable domain responsible for binding to Aβ. We also added a CD8a signal peptide to its N-terminus to express the CAR structure on the cell membrane.
[0070] For the transmembrane domain of CAR, the transmembrane domain of CD8a was selected, and the hinge domain of CD8a was added between it and scFv.
[0071] For the intracellular domain of CAR, the intracellular domain of the TAM receptor family (including TYRO3, AXL and MERTK) was selected.
[0072] In order to identify the expression efficiency of CAR in cells, T2A peptide and green fluorescent protein EGFP were connected after CAR.
[0073] Based on the above content, three human chimeric antigen receptors (with intracellular domains of TYRO3, AXL and MERTK) and three mouse chimeric antigen receptors (with intracellular domains of TYRO3, AXL and MERTK) were designed. The sequence of each chimeric antigen receptor is the following corresponding segment sequence concatenated; In the human chimeric antigen receptor, the amino acid sequence of the signal peptide of CD8a is shown in SEQ ID NO.2, the amino acid sequence of the hinge domain of CD8a is shown in SEQ ID NO.3, the amino acid sequence of the transmembrane domain of CD8a is shown in SEQ ID NO.4, the amino acid sequence of the intracellular domain of TYRO3 is shown in SEQ ID NO.5, the amino acid sequence of the intracellular domain of AXL is shown in SEQ ID NO.6, and the amino acid sequence of the intracellular domain of MERTK is shown in SEQ ID NO.7; In the chimeric antigen receptor of the mouse, the amino acid sequence of the signal peptide of CD8a is shown in SEQ ID NO.8, the amino acid sequence of the hinge domain of CD8a is shown in SEQ ID NO.9, the amino acid sequence of the transmembrane domain of CD8a is shown in SEQ ID NO.10, the amino acid sequence of the intracellular domain of TYRO3 is shown in SEQ ID NO.11, the amino acid sequence of the intracellular domain of AXL is shown in SEQ ID NO.12, and the amino acid sequence of the intracellular domain of MERTK is shown in SEQ ID NO.13.
[0074] The complete CAR structure diagram is as follows Figure 1 shown.
[0075] After testing, it was found that the CAR structure can be stably expressed in cells through lentiviral vector transfection.
[0076] 2. Expressing CAR structure in mouse mononuclear macrophage cell line RAW264.7 and investigating the phagocytic ability of Aβ in vitro By transfecting RAW264.7 with lentivirus and screening with Puromycin, three types of RAW264.7 stably expressing CAR (chimeric antigen receptors of mice containing the TYRO3 intracellular domain, AXL intracellular domain, and MERTK intracellular domain, respectively) were obtained, and the expression efficiency of the CAR structure was verified by detecting the proportion of EGFP positive by flow cytometry, such as Figure 2 As shown in A in the figure (WT is the negative control group, TYRO3, AXL, and MERTK refer to the treatment groups in which RAW264.7 cells were transfected with chimeric antigen receptors with three intracellular domains), the expression efficiency of CAR containing TYRO3, AXL, and MERTK intracellular domains in RAW264.7 cells was 70.6%, 66.4%, and 53.9%, respectively.
[0077] According to previous reports, soluble Aβ protein oligomers (oAβ) are more toxic than insoluble Aβ protein fibrils (fAβ), so oAβ was selected for the experiment. The pHrodo indicator dye has almost no fluorescence at neutral pH, but emits bright fluorescence in an acidic environment. Therefore, oAβ and pHrodo were coupled to obtain oAβ-pHrodo, which can emit fluorescence after being engulfed by cells into lysosomes, so as to characterize the efficiency of cell engulfment of it.
[0078] Wild-type WT and CAR-expressing RAW264.7 cells were co-cultured with oAβ-pHrodo, and the phagocytic efficiency was detected by confocal fluorescence microscopy and flow cytometry after 16 h. Figure 2 B and Figure 2As shown in C, the proportion of CAR-RAW264.7 cells whose intracellular domains are TYRO3, AXL, and METRK that phagocytize oAβ-pHrodo is significantly higher than that of RAW264.7 cells in the WT group.
[0079] 3. Expressing the CAR structure in the human microglial cell line HMC3 and investigating the phagocytic ability of Aβ in vitro By transfecting HMC3 with lentivirus and screening with Puromycin, three stably expressed CAR-HMC3s (human chimeric antigen receptors containing the TYRO3 intracellular domain, AXL intracellular domain, and MERTK intracellular domain) were obtained, and the plasmid transfected with EGFP alone was used as the control group (CTRL). The expression efficiency of the CAR structure was verified by detecting the proportion of EGFP positive by flow cytometry, such as Figure 3 As shown in A.
[0080] CAR-HMC3 cells were then co-cultured with oAβ-pHrodo, and the phagocytic efficiency was detected by flow cytometry after 16 hours. Figure 3 As shown in Figures B and C, the efficiency of CAR-HMC3 in phagocytosing Aβ was significantly higher than that of the control HMC3, and the CAR-HMC3 with AXL as the intracellular domain had the highest phagocytic efficiency among the three.
[0081] In summary, the constructed CAR structure can enable the mouse monocyte macrophage cell line RAW264.7 and the microglial cell line HMC3 to acquire or enhance the phagocytic ability of oAβ.
[0082] 4. Differentiation of human iPSC-derived microglia (iMGL) and verification of the ability of CAR-iMGL to phagocytose Aβ By transfecting human iPSCs with lentivirus and screening with Puromycin, iPSCs stably expressing CAR (with the intracellular domain being AXL) were obtained, and then differentiated into CAR microglia (CAR-iMGL). The differentiation method of human iPSC-derived microglia (iMGL) is as follows: Day 0 The six-well plate was pre-coated with Matrigel (Corning #354277). Human iPSC cells were cultured in the Matrigel-coated six-well plate with mTeSR (STEMCELL Technologies) medium until the confluence was 60%-80%, digested with TryplE Select (ThermoFisher SCIENTIFIC) at room temperature for 5 minutes, neutralized with mTeSR medium, and pipetted into a single cell suspension. The cells were counted and the required number of cells was calculated according to 8000 cells per well. After centrifugation, the Pre-Differentiation medium (first culture medium) was resuspended at 60 μL per well. The cells were transferred to a 96-well U-bottom culture plate (Corning), and then the culture plate was centrifuged at 500 xg for 3 minutes. The cells were observed to aggregate at the bottom of the culture plate, and then placed in an incubator (5% CO2, 37°C) to induce embryoid body (EB) formation.
[0083] Day 1 Gently aspirate 2 / 3 of the medium in the culture plate and add 100 μL of Hematopoietic Differentiation Medium-1. Replace the medium every 3 days.
[0084] Day 6 Gently aspirate 2 / 3 of the culture medium in the culture plate and add 100 μL of Hematopoietic Differentiation Medium-2. At this time, vacuoles can be seen in EBs, indicating that the differentiation effect is good.
[0085] Day 9 If the differentiation goes smoothly, the EB volume and vacuolar volume will increase significantly. Transfer the EB to a six-well plate pre-coated with matrix gel (Corning #354277), add 16 EBs to each well, and culture with fresh Hematopoietic Differentiation Medium-2 medium. The next day after the transfer, the EB will adhere to the wall, and then a large number of suspended cells will appear. Continue to culture for 21 days, replace the fresh Hematopoietic Differentiation Medium-2 medium every 2 days, and collect the suspended cells in the supernatant into a new 6-well plate. The collected suspended cells are cultured with Microglia Differentiation Medium medium, and the medium is replaced every 3 days until microglia are obtained.
[0086] Pre-Differentiation medium: human BMP4 10 ng / mL, Y-27632 10 μM, and STEMdiff™ APEL™ 2 medium; Hematopoietic Differentiation Medium-1: human BMP4 10ng / mL, human FGF-2 10ng / mL, human SCF 100ng / mL, human VEGF-A 50ng / mL, and STEMdiff™ APEL™2 medium; Hematopoietic Differentiation Medium-2: human FGF-2 10ng / mL, human SCF 50ng / mL, human VEGF-A 50ng / mL, human IL-3 25ng / mL, human M-CSF 50ng / mL, human GM-CSF 50ng / mL, human IGF-1 10ng / mL, and STEMdiff™ APEL™2 medium; Microglia Differentiation Medium: ITS-G 2 wt %, glutamine 1x (gibco, 35050061), non-essential amino acids 1x (gibco, 11140050), mercaptoethanol 100 μM, B27 2 wt % (gibco, 17504044), N2 2 wt % (gibco, 17502001), human M-CSF 50 ng / mL, human IL-34 50 ng / mL, human TGF-beta 1 50 ng / mL and DMEM / F12 medium.
[0087] By the above method, human iPSCs are first cultured in vitro into embryoid bodies ( Figure 4 a in A in the figure), and induced differentiation to the mesoderm, and then to the hematopoietic lineage. On the 10th day of differentiation, a large number of suspended hematopoietic stem and progenitor cells began to appear ( Figure 4 A in b), flow cytometry showed that the CD43 positivity rate of suspended cells was 91.1% ( Figure 4 Then, the hematopoietic progenitor cells in the supernatant were collected and induced to differentiate into myeloid microglia (iMGL) ( Figure 4 The A in the d and Figure 4 In A, e), the differentiated cells expressed the microglial marker proteins IBA1 and P2RY12 ( Figure 4 f in A and Figure 4 g in A in ).
[0088] The positive rate of CAR-iMGL was 89.1% ( Figure 4 B in the figure). In the previous article, it was verified in the RAW267.4 cell line that different CAR intracellular domains can effectively phagocytose oAβ, and the phagocytic efficiency is not much different; however, in the human microglial cell line HMC3, the phagocytic effect of the CAR with the AXL intracellular domain is about 1.5 times that of the other two CAR structures. Combined with the above comparison, the CAR structure with the most obvious AXL intracellular domain was finally selected for subsequent functional verification (unless otherwise specified in the following experiments, chimeric antigen receptors refer to chimeric antigen receptors with the AXL intracellular domain).
[0089] CAR-iMGL and WT-iMGL (microglia differentiated from iPSCs without chimeric antigen receptor transfection) were co-cultured with oAβ-pHrodo, and the changes in the phagocytic effect of oAβ-pHrodo over time were detected by incucyte. Figure 4 As shown in Figure C, although both can phagocytose oAβ-pHrodo, the phagocytosis efficiency of CAR-iMGL with the AXL intracellular domain is significantly higher than that of the control group.
[0090] In summary, this experiment successfully differentiated human CAR-iMGL, which has better phagocytic ability of Aβ protein.
[0091] 5. Verification of the ability of CAR microglia to reduce neuroinflammatory response Neuroinflammation usually refers to an inflammatory response in the central nervous system caused by a variety of factors, including infection, tissue damage, amyloid β protein, etc. Neuroinflammation is usually involved by innate immune cells of the central nervous system, mainly microglia and astrocytes. In the state of neuroinflammation, the expression of pro-inflammatory cytokines in the central nervous system increases, including IL-1β, IL-1α, TNF, etc. The release of pro-inflammatory molecules can lead to synaptic dysfunction and neuronal death, thereby aggravating the development of neurodegenerative diseases.
[0092] First, its anti-neuroinflammatory ability was verified in CAR-RAW264.7 cells. In an in vitro culture environment, RAW264.7 cells were stimulated with LPS and Aβ simultaneously to simulate the neuroinflammatory response conditions in vivo, and RNA was extracted 6 hours after treatment for qPCR verification. Figure 5 A- Figure 5As shown in C, when treated with PBS (control group), the expression levels of IL1A, IL1B and TNF of WT and three CAR-RAW264.7 were at low levels. After stimulation with LPS and oAβ (LPS+oAβ), the levels of IL1A, IL1B and TNF expressed by WT-RAW264.7 increased sharply and were significantly higher than the expression levels of the three CAR-RAW264.7 cells. It can be seen that compared with WT, the three CAR-RAW264.7 have a strong ability to resist neuroinflammatory response.
[0093] Afterwards, the anti-neuroinflammatory ability of CAR-iMGL expressing the intracellular domain of AXL was further verified. In an in vitro culture environment, human iMGL cells were stimulated with LPS and oAβ at the same time, and RNA was extracted for qPCR verification after 6 hours of treatment. Figure 5 As shown in D, the expression of IL1A and IL1B of CAR-iMGL expressing the intracellular domain of AXL after stimulation was significantly lower than that of WT-iMGL, while TNF was similar to that of the WT group.
[0094] In summary, the constructed CAR structure can enable macrophages or microglia to have the ability to resist neuroinflammatory response.
[0095] 6. Study on the ability of CAR-iMGL to phagocytose amyloid β protein in mice According to a previous report by Zhen et al. (XU Z, RAO Y, HUANG Y, et al. Efficient Strategies for Microglia Replacement in the Central Nervous System [J]. CellRep, 2020, 32(6): 108041.), feed containing the CSF1R inhibitor PLX5622 can effectively eliminate the original microglia in mice, thereby improving the efficiency of allogeneic microglia transplantation. The inventors found through experiments that compared with the control feed, the number of IBA1-positive microglia in the brain of C57BL / 6J mice was significantly reduced after two weeks of feeding with PLX5622 feed ( Figure 6 A in Figure 1, different colors represent the staining results of DAPI and IBA1), demonstrating the feasibility of PLX5622 in eliminating microglia.
[0096] Afterwards, the 4-month-old Alzheimer's model mouse FAD4T was selected to investigate the ability of CAR-iMGL to phagocytize amyloid β protein. Figure 6As shown in Figure B, FAD4T mice were first fed PLX5622 feed for 2 weeks to eliminate microglia in the mouse brain, and then the CAR-iMGL cells expressing the AXL intracellular domain constructed by the present invention were injected into the brain. 2*10 5 cells, and then the feed was changed to ordinary feed and the mice were killed on the seventh day for frozen sections and immunofluorescence staining. Figure 6 As shown in C (different colors represent the staining results of DAPI and IBA1, and the results of EGFP fluorescence detection), most of the EGFP-positive CAR-iMGL cells gathered at the injection site and expressed the microglial marker IBA1. However, it was found that CAR-iMGL has the potential to migrate to areas other than the injection site. For example: Most of the CAR-iMGL in mice #1 gathered in the hippocampal trough, and a small number of cells migrated to the pyramidal layer, stratum radiatum, and molecular layer of the hippocampus, and a small number of cells migrated to the cerebral cortex. Most of the CAR-iMGL injected into the brain of mice #2 gathered in the dentate gyrus of the hippocampus, but were also distributed in the molecular layer and stratum radiatum of the hippocampus.
[0097] Then, immunofluorescence staining was performed using the Aβ protein antibody 6e10, and Z-stack photography was performed using a confocal microscope to observe the co-localization of CAR-iMGL and Aβ. After co-localization analysis using Imaris software, it was found that some Aβ proteins were engulfed by CAR-iMGL in the cytoplasm. Figure 6 D in the figure shows two cases of CAR-iMGL engulfing Aβ, #1 and #2, where the green marker is CAR-iMGL and the white marker is Aβ ( Figure 6 D (left). The phagocytosed Aβ was analyzed by co-localization analysis using Imaris software and is marked in yellow ( Figure 6 After 3D reconstruction analysis by Imaris software, the localization relationship between Aβ, engulfed Aβ and CAR-iMGL is more intuitively displayed ( Figure 6 To further verify, we used Congo Red dye to stain Aβ protein and took Z-stack photos using a confocal microscope, and found that Aβ plaques were engulfed by CAR-iMGL ( Figure 6 E in.
[0098] In summary, exogenously injected CAR-iMGL can migrate in the mouse brain and phagocytose Aβ protein.
[0099] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A chimeric antigen receptor targeting amyloid β protein, characterized in that: From N-terminus to C-terminus, it includes the extracellular domain, the hinge domain of CD8a, the transmembrane domain of CD8a, and the intracellular domain; The extracellular domain includes a CD8a signal peptide and an anti-amyloid β protein scFv from the N-terminus to the C-terminus; the amino acid sequence of the scFv is shown in SEQ ID NO.1; The intracellular domain includes the intracellular domain of TYRO3, the intracellular domain of AXL or the intracellular domain of MERTK; The chimeric antigen receptor is a human chimeric antigen receptor or a mouse chimeric antigen receptor; In the human chimeric antigen receptor, the amino acid sequence of the signal peptide of CD8a is shown in SEQ ID NO.2, the amino acid sequence of the hinge domain of CD8a is shown in SEQ ID NO.3, the amino acid sequence of the transmembrane domain of CD8a is shown in SEQ ID NO.4, the amino acid sequence of the intracellular domain of TYRO3 is shown in SEQ ID NO.5, the amino acid sequence of the intracellular domain of AXL is shown in SEQ ID NO.6, and the amino acid sequence of the intracellular domain of MERTK is shown in SEQ ID NO.7; In the chimeric antigen receptor of the mouse, the amino acid sequence of the signal peptide of CD8a is shown as SEQ ID NO.8, the amino acid sequence of the hinge domain of CD8a is shown as SEQ ID NO.9, the amino acid sequence of the transmembrane domain of CD8a is shown as SEQ ID NO.10, the amino acid sequence of the intracellular domain of TYRO3 is shown as SEQ ID NO.11, the amino acid sequence of the intracellular domain of AXL is shown as SEQ ID NO.12, and the amino acid sequence of the intracellular domain of MERTK is shown as SEQ ID NO.
13.
2. The chimeric antigen receptor according to claim 1, characterized in that The chimeric antigen receptor also includes a fluorescent tag; The fluorescent tag includes EGFP.
3. The chimeric antigen receptor according to claim 2, characterized in that The fluorescent tag is linked to the intracellular domain via a connecting peptide; The amino acid sequence of the connecting peptide is shown in SEQ ID NO.
14.
4. Use of the chimeric antigen receptor according to any one of claims 1 to 3 in the following a or b: a. Preparation of products for removing amyloid β protein; b. Prepare products that reduce neuroinflammatory responses.
5. A nucleotide, characterized in that The nucleotide comprises a nucleotide sequence encoding the chimeric antigen receptor according to any one of claims 1 to 3.
6. A carrier, characterized in that The vector carries the nucleotide according to claim 5.
7. A macrophage, characterized in that: The macrophage carries the nucleotide of claim 5, or contains the vector of claim 6, or expresses the chimeric antigen receptor of any one of claims 1-3.
8. A microglia cell, characterized in that: The microglia carry the nucleotide described in claim 5, or contain the vector described in claim 6, or express the chimeric antigen receptor described in any one of claims 1-3.
9. The microglia cell according to claim 8, characterized in that The microglia are obtained by differentiation of induced pluripotent stem cells, comprising the following steps: Inducing pluripotent stem cells to form embryoid bodies by culturing them in a first culture medium; then culturing the embryoid bodies in a second culture medium to induce differentiation of hematopoietic stem and progenitor cells; then culturing them in a third culture medium to induce the production of hematopoietic stem and progenitor cells and inducing their differentiation into myeloid lineage; finally, collecting the differentiated hematopoietic stem and progenitor cells, and culturing them in a fourth culture medium to induce differentiation into microglia; The first culture medium comprises: human BMP4 10 ng / mL, Y-27632 10 μM and STEMdiff™ APEL™2 culture medium; The second culture medium comprises: human BMP4 10 ng / mL, human FGF-2 10 ng / mL, human SCF 100 ng / mL, human VEGF-A 50 ng / mL and STEMdiff™ APEL™2 culture medium; The third culture medium comprises: human FGF-2 10 ng / mL, human SCF 50 ng / mL, human VEGF-A 50 ng / mL, human IL-3 25 ng / mL, human M-CSF 50 ng / mL, human GM-CSF 50 ng / mL, human IGF-1 10 ng / mL and STEMdiff™ APEL™2 culture medium; The fourth culture medium comprises: ITS-G 2 wt %, glutamine 1x, non-essential amino acids 1x, mercaptoethanol 100 μM, B27 2 wt %, N2 2 wt %, human M-CSF 50 ng / mL, human IL-34 50 ng / mL, human TGF-beta 1 50 ng / mL and DMEM / F12 culture medium; The second culture medium is cultured for 4-6 days; The third culture medium is cultured for 22-26 days.
10. The microglia cell according to claim 9, characterized in that The second culture medium is replaced every 3 days; The third culture medium was replaced every 2 days.
Citation Information
Patent Citations
Method and kit for inducing and generating microglial cells by multi-potential stem cells
CN110205295A
Modified monocytes / macrophages / dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates
CN112004823A
Chimeric antigen receptor for pathological protein aggregate removal and application of chimeric antigen receptor
CN112194726A
Method for preparing microglial cell-like cells by using pluripotent stem cells
CN114426951A
Chimeric antigen receptor, microglial cell differentiated from human pluripotent stem cells and expressing chimeric antigen receptor and application of microglial cell
CN118005806A
Cited By
Chimeric antigen receptor molecule and application thereof
CN122562967A
